不规则
发表于 2025-3-25 06:52:28
http://reply.papertrans.cn/83/8285/828455/828455_21.png
Host142
发表于 2025-3-25 10:49:39
Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma,ival and delay of radiologic tumor progression. These benefits were demonstrated in the absence of a high rate of overall response and the magnitude of this improvement varies considerably from patient to patient. Several hypotheses have tried to address the reason for this variability, giving birth
Parley
发表于 2025-3-25 14:20:13
http://reply.papertrans.cn/83/8285/828455/828455_23.png
Respond
发表于 2025-3-25 16:14:18
http://reply.papertrans.cn/83/8285/828455/828455_24.png
侵略
发表于 2025-3-25 23:37:21
Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma,an now be easily tracked, which will provide novel insights into cancer evolution and mechanisms of treatment resistance. This will be critical to provide novel therapeutic targets for second and third line therapies in hepatocellular carcinoma.
LUCY
发表于 2025-3-26 03:38:44
http://reply.papertrans.cn/83/8285/828455/828455_26.png
商店街
发表于 2025-3-26 06:33:25
Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance,omote resistance. Understanding the interactions of the components of the liver tumor microenvironment with cancer cells will be critical to design strategies to overcome resistance and improve the therapeutic efficacy of current and future therapies.
ASSAY
发表于 2025-3-26 11:56:25
http://reply.papertrans.cn/83/8285/828455/828455_28.png
DIS
发表于 2025-3-26 14:26:43
http://reply.papertrans.cn/83/8285/828455/828455_29.png
加入
发表于 2025-3-26 19:36:41
http://reply.papertrans.cn/83/8285/828455/828455_30.png